首页> 外文期刊>Clinical ophthalmology >Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization
【24h】

Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization

机译:黄斑脉络膜新生血管患者玻璃体内贝伐单抗相关的皮疹

获取原文
           

摘要

Purpose: The purpose of this observational case report is to describe a case of skin rash after intravitreal use of bevacizumab.Methods: A 50-year-old man with choroidal neovascularization in the right eye due to age-related macular degeneration was treated with three intravitreal injections of bevacizumab.Results: Twelve days after the first injection, the patient developed a maculopapular rash on his forehead and on both temporal regions around his eyes. The rash disappeared eight days after treatment with topical corticosteroids. A skin rash with the same distribution reappeared 14 days after the second and 10 days after the third injection. Similarly, it disappeared five and seven days after the use of the same treatment. The follow-up period was 15 months after the third injection. During the follow-up period the rash did not reappear.Conclusion: This case report may initiate further investigation of similar cases to support this observation, as there are a lack of reports of skin rash after intravitreal administration of bevacizumab.
机译:目的:本观察病例报告的目的是描述玻璃体内注射贝伐单抗后出现皮疹的病例。方法:对一名年龄与年龄相关的黄斑变性导致右眼脉络膜新生血管形成的50岁男性进行了3种治疗结果:第一次注射后第十二天,患者的额头和眼睛周围的两个颞区域都出现了斑丘疹。用局部糖皮质激素治疗八天后皮疹消失。在第二次注射后14天和第三次注射后10天,再次出现相同分布的皮疹。同样,使用相同的治疗后五天和七天,它消失了。随访期为第三次注射后15个月。在随访期间,皮疹没有再出现。结论:由于缺乏玻璃体内注射贝伐单抗后皮疹的报道,本病例报告可能会启动对相似病例的进一步调查以支持这一观察。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号